NEWPORT BEACH, Calif.–(BUSINESS WIRE)–ROTH Capital Partners (“ROTH”), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that Dr. Zegbeh Jallah has joined the firm’s healthcare research team.
Dr. Zegbeh Jallah is a Director and Research Analyst covering biotechnology. At ROTH, her research coverage is expected to include SMID cap Biotechnology companies across the therapeutic space. Her initial focus is on companies developing novel drugs for Autoimmune and Oncology indications. Zegbeh was most recently a Senior Biopharma Research Strategist at Piper Jaffray, where she launched Piper’s BioInsights Thematic Publication, a report she published in partnership with the Biopharma Sector Analysts. Prior to joining Piper, Zegbeh was at BTIG where she was a Vice President in the Biotech Equity Research Department. While at BTIG, she built expertise in covering companies developing Gene, CAR-T Cell, Bi-Specific Antibodies, and other novel therapies. She holds a Ph.D in Biomedical Engineering from the University of Pittsburgh, and is a trained scientist with over 10 years of research experience, which she has leveraged and continues to leverage to provide expert due diligence on early stage Biotechnology companies.
Jeff Martin, CFA – Director of Research, commented, “ROTH continues to invest in biotechnology research talent to enhance the strength of our Healthcare platform. I’m pleased to welcome Dr. Jallah to our thought-leading biotechnology research team. Her strong academic background combined with her extensive experience in covering gene therapy and oncology companies will undoubtedly serve our clients well.”
Dr. Jallah commented, “I am very excited to have joined the biotechnology team at ROTH, which has distinguished itself with industry leading coverage across several therapeutic areas. Our high quality research has proven invaluable to clients, and with the many novel treatments on the horizon, a team with deep scientific insights is instrumental to navigating the therapeutic landscape. I look forward to working with the team at ROTH as we continue to broaden and deepen our coverage across the therapeutic space, to discover unique investment opportunities.”
“We are excited to have Zegbeh join our healthcare research team,” said Byron Roth, CEO of ROTH Capital Partners. “Her addition further demonstrates our unwavering commitment to the life sciences sector. I’m confident that Zegbeh’s expertise in biotechnology will enhance our ability to continue to build upon our over 10-year track record of success in assisting both companies and investors in the healthcare sector.”
About Roth Capital Partners, LLC:
ROTH Capital Partners, LLC (ROTH), is a relationship-driven investment bank focused on serving emerging growth companies and their investors. As a full-service investment bank, ROTH provides capital raising, M&A advisory, analytical research, trading, market-making services and corporate access.
Headquartered in Newport Beach, Calif., ROTH is privately-held and owned by its employees, and maintains offices throughout the U.S. For more information on ROTH, please visit www.roth.com.
Contacts
Investor and Media Contact: ROTH Capital Partners, Isabel Mattson-Pain, Director of Marketing, Imattson-pain@roth.com, 949-720-7117